non-small cell lung cancer Archives
Targeted cancer drug during pregnancy
Aug. 2, 2022—The targeted cancer therapy alectinib was safe as a treatment for lung cancer during two pregnancies in a patient with non-small cell lung cancer, according to a case report from Vanderbilt physicians.
Study reveals need for matching targeted therapies with EGFR subtypes
Jul. 28, 2022—A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
Molecular testing across tumor types
Apr. 25, 2022—The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.
Vanderbilt researchers present new data on clinical trials at ASCO 2021
May. 26, 2021—Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.
